FDA committee backs Lilly's prasugrel

FDA staff say Eli Lilly's long-delayed blood thinner prasugrel has clear benefits compared with other anti-clotting meds on the market, but its use may need to be restricted to curb the potential of bleeding side effects; an advisory panel will review the potential new drug later this week. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.